Latest Stock Market News

Biocon Biologics share which constitutes 45% of revenues reported 29% YoY growth to Rs Rs 977 crore in Q1FY23, while the generic business rose 19% to Rs 580 crore.Biocon said that its net profit and margins would have been much higher, had it not been for higher R&D and other expenses.

"The Securities and Exchange Board of lndia (Sebi) has granted its in-principle approval for the change in control of HDFC Property Ventures Limited, a wholly-owned subsidiary of HDFC Ltd which is the investment manager of HDFC India Real Estate Fund III (HIREF III)," HDFC Ltd said in a regulatory filing on Wednesday.

Rajan Sethuraman, Chief Executive Officer, Latent View Analytics, said, “Our Q1FY23 performance was in-line with our expectations, and we are happy to report revenue growth of 37% on a YoY basis. I am pleased to share that our investments in the front-end sales team, building capabilities, assets and accelerators are showing results

Total revenue rose to Rs 2,217 crore in the first quarter as compared with Rs 1,808 crore in the year-ago period, Biocon said in a regulatory filing.Biocon Executive Chairperson Kiran Mazumdar-Shaw said revenues grew as a result of robust growth in both biosimilar and generics verticals.

>> For more such web stories click on the ET icon below

The Dow Jones Industrial Average rose 103.51 points, or 0.33%, at the open to 31,865.05.

This was achieved on the back of strong response to our new launches in Bangalore and Gurgaon as well as robust sustenance sales across our portfolio. Our industrial leasing, at Rs 118 crore, continued its momentum,” said Arvind Subramanian, MD & CEO, Mahindra Lifespace Developers.

The company’s assets under management (AUM) grew by 28% to Rs 2.04 lakh crore at the end of June 2022 from Rs 1.59 lakh crore a year ago. New loans booked during the first quarter increased 60% to 7.42 million from 4.63 million a year ago.

"The company has access to borrowing facilities worth Rs 530 crore, of which Rs 480 crore remained unutilised as on 30th June, 2022," EIH stated.EIH stated that the consequences of the Covid-19 outbreak on the company’s and its subsidiaries’ business for the year ended 31st March, 2022 and 31st March, 2021 had been severe.

The company attributed this to the change in the effective tax rate for Q1FY23 on account of a drop in SEZ profits exemption u/s 10AA to 50% from FY23 for 5 years. The company said it is evaluating switching over to composite rate without availing any exemptions.